Replies to post #235172 on Biotech Values

[jbog]

Regarding ENTA my conclusion wasn't whether it would need to raise money or not but rather were they spending their money properly on targets that would show promise in the future.

Considering they only have around 20 million shares outstanding any secondary wouldn't hurt a bit so that didn't concern me at all.

I sold about a 1 1/2 years ago because I thought they were headed in very competitive areas and it would be a long slog to get to any finish line. I do plan to get back in when I see something positive.

As Always Good Luck

[DewDiligence]

I think viral panels are going to be SOC for anyone that has [upper respiratory tract] symptoms in the future post-covid.

Yes—see #msg-172175433.